-+ 0.00%
-+ 0.00%
-+ 0.00%

Atossa says FDA grants rare pediatric disease designation for (Z)-endoxifen in MAS

PUBT·05/04/2026 12:32:19
Listen to the news
Atossa says FDA grants rare pediatric disease designation for (Z)-endoxifen in MAS
  • Atossa Therapeutics received FDA Rare Pediatric Disease designation for (Z)-endoxifen to treat McCune-Albright Syndrome in females.
  • Designation could make company eligible for a Priority Review Voucher if a qualifying marketing application is approved.
  • Disclosed Priority Review Voucher sales over past 18-24 months ranged from about $100 million to $205 million.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atossa Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: SF49809) on May 04, 2026, and is solely responsible for the information contained therein.